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ABSTRACT
Background    To differentiate the features of electro-
encephalography (EEG) after status epileptics in febrile 
children with final diagnosis of either febrile seizure (FS) 
or acute encephalopathy for an early diagnosis.
Methods    We retrospectively collected data from 68 
children who had status epilepticus and for whom EEGs 
were recorded within 120 h. These included subjects 
with a final diagnosis of FS (n = 20), epileptic status 
(ES; n = 11), acute encephalopathy with biphasic sei-
zures and late reduced diffusion (AESD; n = 18), mild 
encephalopathy with a reversible splenial lesion (MERS; 
n = 7), other febrile encephalopathies (n = 10), hypoxic-
ischemic encephalopathy (n = 1), and intracranial bleed-
ing (n = 1). Initially, all EEGs were visually assessed 
and graded, and correlation with outcome was explored. 
Representative EEG epochs were then selected for quan-
titative analyses. Furthermore, data from AESD (n = 7) 
and FS (n = 16) patients for whom EEG was recorded 
within 24 h were also compared.
Results    Although milder and most severe grades of 
EEG correlated with neurological outcome, the outcome 
of moderate EEG severity group was variable and was 
not predictable from usual inspection. Frequency band 
analysis revealed that solid delta power was not signifi-
cantly different among the five groups (AESD, MERS, 
FS, ES and control), and that MERS group showed the 
highest theta band power. The ratios of delta/alpha and 
(delta + theta)/(alpha + beta) band powers were signifi-
cantly higher in the AESD group than in other groups. 
The alpha and beta band powers in EEGs within 24 h 
from onset were significantly lower in the AESD group. 
The band powers and their ratios showed earlier im-
provement towards 24 h in FS than in AESD.
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Conclusion    Sequential EEG recording up to 24 h 
from onset appeared to be helpful for distinction of 
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The term acute encephalopathy (AE) encompasses vari-
ous etiologies with acute insult to the brain and clinical 
manifestations of seizures, impaired consciousness and 
other neurological symptoms. This includes bacte-
rial meningitis, viral encephalitis, hypoxic-ischemic 
encephalopathy (HIE), head injury, cerebrovascular 
disorders, and encephalopathies secondary to hepatic or 
renal failure.1, 2 Among others, AE as a complication of 
common viral (rarely bacterial) infections often affects 
young children and causes death or severe neurological 
sequelae. This subgroup of AE is a main cause of acute 
cerebral injury in Japan.3, 4 Acute encephalopathy with 
biphasic seizures and late reduced diffusion (AESD) is 
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the most frequent subtype,3, 5 characterized by no abnor-
malities on magnetic resonance imaging (MRI) at the 
disease onset, and evolution of second phase of encepha-
lopathy following 4–7 days of latent period, accompa-
nied by reduced diffusion due to cytotoxic edema.6–8 It 
is often difficult to identify which patient represents the 
first phase of AESD, and which just manifests with a 
prolonged febrile seizure (FS) with favorable outcome. 
Given that a sustained increase in excitatory transmitters 
play a role in the provocation of second phase in AESD,8 
early initiation of treatment may lead to a better out-
come. Therefore, early diagnosis of AESD is desirable 
for decision of treatment strategy that possibly prevents 
or ameliorates the second phase of AESD to improve the 
prognosis of this burden for previously healthy children.
 Electroencephalogram (EEG) during the acute phase 
of AE shows diffuse slowing and attenuation/ flattening 
in encephalopathy due to various etiologies,1, 9 includ-
ing AESD.10, 11 However, it is not easy to distinguish AE 
from prolonged FS or infection-induced epileptic status 
(ES), because diffuse delta activities are also often seen 
in these conditions for a few days after seizure onset.10, 11 
The aim of this study was to examine whether qualita-
tive analysis of EEGs during acute phase of AEs was 
able to predict the prognosis, and specifically to find any 
findings that distinguish EEGs of AESD from those of 
other disorders including FS and ES, through quantita-
tive EEG analysis by using fast Fourier transform (FFT). 
SUBJECTS AND METHODS
Subjects
This study enrolled children who manifested with acute 
symptoms of status epilepticus (SE) and impaired con-
sciousness, who was referred to Tottori University Hos-
pital, Shimane University Hospital, Seirei-Hamamatsu 
Hospital, Shimane Prefectural Central Hospital, Kyushu 
University Hospital, Kagoshima University Hospital, 
Matsue Red-Cross Hospital, Tsuyama Central Hospital, 
and Saitama Children’s Medical Center between Decem-
ber 2001 and June 2014. Clinical data including the EEG 
tracings were retrospectively collected. SE was defined 
as any seizure > 30 min or a series of recurrent seizures 
beyond 30 min. In a narrow sense, AE in this study was 
defined according to the previously proposed criteria3–5: 
i) acute onset of impaired consciousness accompanied 
by seizures during a febrile infection; ii) exclusion of 
well-defined central nervous system inflammation, head 
trauma, cerebrovascular disease, toxic encephalopathy, 
and systemic and metabolic diseases and iii) normal cell 
count in CSF and negative viral and bacterial culture of 
CSF samples. AE subtypes were classified into AESD, 
acute necrotizing encephalopathy (ANE), hemiconvul-
sion-hemiplegia syndrome (HHS), Reye-like syndrome, 
and clinical mild encephalitis/encephalopathy with a 
reversible splenial lesion (MERS) according to the pre-
vious reports.4, 12, 13 Sixty-eight patients (mean age ± 
SD; 3.5 ± 3.1, 38 males and 30 females) were identified, 
including 34 patients with AE, 20 with FS, and 11 with 
ES, 1 with hypoxic-ischemic encephalopathy (HIE), 
and 1 with intracranial bleeding (Table 1). All of these 
patients underwent EEG recording during acute periods. 
A control group (n = 13, aged 4.8 ± 3.2 years, M:F = 8:5) 
was also selected whose EEG were recorded in Tottori 
University Hospital. They showed normal development 
without previous history of AE or other brain injuries; 
simple FS in 6, attention deficit hyperactivity disorder in 
2, headache in 2, benign infantile convulsion in 1, breath 
holding spell in 1, shuddering attack in 1.
 The study protocol was approved by institutional 
review boards.
EEG recordings
Seventy two EEGs of 20–30 min were recorded in 68 
patients during the acute phase, at period of 1–120 h 
(mean ± SD; 21 ± 25) from the onset of neurological ill-
ness. For the 4 patients (2 AESD and 2 FS) with repeat-
ed EEG recordings, the initial ones were used for visual 
and quantitative analyses. EEGs were recorded during 
sleep or unconsciousness state after antiepileptic injec-
tions; those at later periods up to 120 h were recorded 
during sleep induced by sedative agents. Electrodes were 
placed according to the international 10–20 system us-
ing at least 13 EEG channels (Fp1, Fp2, F3, F4, Cz, C3, 
C4, P3, P4, O1, O2, T3 and T4). Ground electrodes were 
attached to the forehead (Fpz). EEG data with bipolar 
montages were used for visual assessment and spectrum 
analysis to avoid the influence by artifacts due to body 
movements involving the scalp and earlobe electrodes. 
Recordings were carried out using the Neuropack EEG 
system (Nihon-Koden, Tokyo, Japan) and signals were 
downsampled at 1 kHz, then EEG was resampled at 200 
or 500 Hz and stored on the hard disk for analysis. The 
sensitivity was set at 10μV/mm with low-frequency fil-
ter of 0.5 Hz, high-frequency filter of 60 Hz. The notch 
filter was used at 60 Hz for data from western districts 
of Japan and at 50 Hz for data from eastern districts. Pa-
tients who had been evaluated for burst suppression and 
epileptiform activity (periodic or rhythmic spikes, sharp 
waves, spike-waves) were excluded in this study. 
Visual EEG assessment
EEG patterns used for power spectrum analysis were 
classified into five grades by an epileptologist (YM) who 
was blind to the clinical information, according to the 
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Table 1. Clinical characteristics of the patients
Patient age of onset Sex Diagnosis Accompanying symptoms and/or infectious agents identified
EEG from
the onset (h)
Therapy for neurological 
symptom Prognosis
  1   3 y 7 m M AESD –   44 DZP, MDZ Most Severe (in -hospital death)
  2   5 y 2 m M AESD –     2 MDZ, PB Most Severe(in -hospital death)
  3   5 y 4 m F AESD Fever, vomiting   33 DZP Severe
  4 11 m F AESD Exanthema subitum   34 DZP, MDZ Severe
  5   1 y 5 m F AESD Influenza 120 DZP, PB Severe
  6   1 y 1 m M AESD Exanthema subitum   20 DZP, MDZ Severe
  7   1 y 11 m M AESD Bronchitis     1 None Moderate-mild
  8   2 y 11 m M AESD Influenza     2 None Moderate-mild
  9   1 y 10 m M AESD Influenza   20 DZP, MDZ Moderate-mild
10   1 y 4 m M AESD Upper respiratory infection   66 fPHT Moderate-mild
11–18   8 m–5 y 4 M/4 F AESD
Exanthema subitum, gastroen-
teritis (Rotavirus), fever, nasal 
discharge, unclassified
    1 to 101 DZP, MDZ, PB, fPHT,propofol or none in 5 Normal
19–25   1 y 0 m–9 y 0 m 5 M/2 F MERS
Influenza, gastroenteritis 
(Rotavirus), adenovirus, fever, 
clouding of consciousness
    3 to 39 DZP, MDZ, fPHTor none Normal
26 11 m F Reye-likesyndrome Exanthema subitum     5 DZP
Most Severe
(in -hospital death)
27   1 y 8 m M Reye-likesyndrome Upper respiratory infection     3 DZP, MDZ Normal
28   8 m M ANE Upper respiratoryinflammation   77 DZP, PB Normal
29   4 y M HHS Influenza     3 fPHT, vitamin compoundsNormal
30–35   2 m–11 y 6 m 3 M/3 F AE(unclassified) Fever, vomiting     8 to 34
DZP, MDZ, TPL, PB,
or none in 2 Severe
36   1 y 7 m F HIE –   11 None Most severe
37   1 y 4 m M Intracranialbleeding
Upper respiratory
inflammation   19 PB Most severe
38–57 11 m–9 y 3 m 9 M/11 F FS Influenza, upper respiratory inflammation, fever     1 to 105
DZP, MDZ, TPL, PB,
or none in 4 Normal
58–68   1 y 3 m–16 y 11 m6 M/5 F ES –  0.5 to 101 DZP, MDZ, or none in 1 Normal
–: symptoms other than fever and neurological manifestations were absent and no infectious agents were identified, AESD, acute enceph-
alopathy with biphasic seizures and late reduced diffusion; DZP, diazepam; ES, epileptic status; F, female; fPHT, fosphenytoin; FS, febrile 
seizure; HHS, hemiconvulsion-hemiplegia syndrome; HIE, hypoxic ischemic encephalopathy; M, male; m, month(s); MDZ, midazolam; 
MERS, mild encephalitis/encephalopathy with a reversible splenial lesion; PB, phenobarbital; none, no medication; TPL, thiopental; y, 
year(s). 
scale reported by Synek et al.9 : Grade 1; normal or mild 
abnormality with alpha activity but little, scattered theta 
activity, Grade 2; mild signs of encephalopathy with 
dominant activity in the theta frequency range, with 
some alpha and delta waves, Grade 3; moderate signs of 
encephalopathy characterized by dominant widespread 
delta activity, regular or irregular, with little activity in 
other frequency range, Grade 4; severe signs of encepha-
lopathy with epileptiform discharges or with low-output 
EEG, Grade 5; signs of vegetative encephalopathy with 
frequent isoelectric EEG. The EEG data with bipolar 
montages (Fp1-F3, Fp2-F4, F3-C3, F4-C4, C3-P3, C4-
P4, P3-O1 and P4-O2) were analyzed.
Quantitative EEG analysis
For the quantitative analyses, EEG power spectrum was 
calculated with a fast Fourier transform (FFT) by the 
MATLAB software, R2013 student version (The Math-
Works, Natick, MA). A representative, artifact-free five 
5-second epochs were selected from each record and 
was averaged before absolute FFT. We excluded sudden 
deflection, such as epileptiform discharges and vertex 
sharp transients. Subsequently, the power spectrum 
was calculated for frequencies between 0.5 and 60 Hz 
with frequency step of 0.4 Hz in sampling 200 Hz and 
0.2Hz in sampling 500Hz, and then averaged across the 
following bands: delta (0.5–3.9 Hz), theta (4.0–7.9 Hz), 
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alpha (8.0–12.9 Hz), beta (13.0–19.9 Hz), and gamma 
(20.0–39.9Hz) frequency bands. The ratios of different 
EEG frequency bands reported by Stewart J et al14 : the 
delta-alpha ratio (the delta band power divided by the 
alpha band power) and the (delta + theta)/(alpha + beta) 
ratio (the sum of delta plus theta band power divided by 
the sum of alpha plus beta band power) were also evalu-
ated to enhance the identification of increased power of 
slow waves and decreased power of faster waves. These 
power values were averaged in each etiology group, 
i.e. AESD, FS, MERS, ES and controls, and used for 
analysis. We then selected patients with AESD (n = 7) 
and FS (n = 16) for whom EEGs were recorded within 
24 h from onset, and compared the quantitative data to 
clarify whether any difference are present between these 
groups. In addition to the aforementioned FFT variables 
in average, we illustrated the temporal distribution of the 
variables through the 24 h, as well as the evolution in the 
4 patients for whom EEGs were re-examined within 24 h.
Neurological sequelae in clinical prognosis 
The intellectual (IQ) or development quotient (DQ) later 
in the chronic phase was assessed in each patient by the 
Enjoji or Tanaka-Binet developmental scales. Neurologi-
cal sequelae were graded into 4 categories: most severe; 
in-hospital death during acute periods, clinical brain 
death or vegetative state with brainstem dysfunction, se-
vere; IQ/DQ < 35, moderate-mild; IQ/DQ = 35–69, and 
normal; IQ/DQ ≥ 70).
Statistical analysis
The EEG power spectra of each etiology group were 
analyzed using the Tukey way after using Kruskal-Wal-
lis test. The proportion of patients for whom individual 
anticonvulsive agents in each etiology group, i.e. AESD, 
FS, MERS and ES was analyzed with Chi-square test. 
The comparison between AESD and FS was carried 
out by the Mann-Whitney U test. Regression lines for 
the spectrum data from AESD and FS during 24 h were 
drawn by the recording period as the independent vari-
able and the power value as the dependent variable. P 
values of < 0.05 were considered statistically significant. 
The IBM SPSS Statistics 20 (IBM, Tokyo, Japan) was 
used for these statistical tests.
RESULTS
Clinical characteristics
Of the 68 participants, 14 resulted in hospital death or 
neurological sequelae: classified as most severe progno-
sis in 5 patients (in-hospital deaths in 3 and vegetative 
state in 2), severe prognosis in 5 patients, and moderate-
mild prognosis in 4 patients. The prognosis of AESD 
was most severe in 2 patients, severe in 4 patients, 
moderate-mild in 4 patients, and normal in 8 patients. 
All 7 patients with MERS had a normal prognosis. 
Twenty FS and 11 ES patients all showed a full recovery 
(Table 1). Regarding the treatment for termination of 
initial SE, which may increase fast activity on the EEG, 
diazepam was used in 9 AESD, 2 MERS, 2 Reye-like 
syndrome, 1 ANE, 10 FS, 7 ES, and 1 unclassified AE. 
Midazolam was used in 7 AESD, 1 MERS, 1 Reye-like 
syndrome, 8 FS, 4 EP, and 1 unclassified AE. Both of 
these agents were administrated in 5 AESD, 1 MERS, 
1 Reye-like syndrome, 4 FS, 1 ES, and 1 unclassified 
AE. Phenobarbital was used in 4 AESD, 1 ANE, 1 in-
tracranial bleeding, 3 FS, and 2 unclassified AE. The 
proportion of usage of these agents was not statistically 
significant among the AESD, MERS, FS and ES groups. 
Other medications included thiopental in 4, propofol in 
1, fosphenytoin in 4, and vitamin compounds in 1. The 
medication used in the 5 most severe patients were diaz-
epam in 2, midazolam in 2, phenobarbital in 3, and no 
medication in 1. All 5 severe patients were treated with 
diazepam in 5, midazolam in 3, and phenobarbital in 1. 
Two of 4 moderate-mild patients were treated with diaz-
epam in 1, midazolam in 1, and fosphenytoin in 3. 
Visual EEG assessment
The severity grades of acute phase EEGs were variable 
in the AESD, FS, and ES groups, and distinction of 
these etiologies by visual inspection were impossible be-
tween EEGs of each grade (Fig. 1, Table 2). The EEGs 
in MERS was graded to 1–3, consistent with the favor-
able outcome of this patient group (Table 2). EEGs in 
some MERS patients were characterized by high ampli-
tude theta activity with fronto-occipital predominance. 
As shown in Table 2, there was a considerable overlap 
among AESD, FS and ES groups, particularly in grades 
3 and 4.
 As for the correlation between the visual EEG grad-
ing and the neurological sequelae (Table3), all but 1 pa-
tients (18/19, 95.0%) in grades 1 and 2 were normal and 
one patient had mild-moderate sequelae. In Grades 3, 
although most patients were normal, some patients (5/36, 
14.0%) had neurological sequelae. In Grade 4, although 
5 patients were normal, the other patients (5/10, 50.0%) 
had neurological sequelae. In Grade 5, all 3 patients 
were suffering from most severe sequelae.
EEG spectrum analysis of different etiology groups 
(Fig. 2, Table 4)
The absolute value of spectrum band powers showed no 
significant difference among the 5 groups in the delta 
band (Fig. 2A). In the theta band, the MERS group 



















Fig. 1. Representative EEG of each severity grade in patients with A: AESD, 
B: MERS, C: prolonged FS and D: ES. 
AESD, acute encephalopathy with biphasic seizures and late reduced diffu-
sion; EEG, electroencephalogram; ES, epileptic status; FS, febrile seizure; 
MERS, mild encephalitis/encephalopathy with a reversible splenial lesion.
Table 2. Severity grades on visual assessment of EEGs in children after status epilepticus due to each etiology
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
AESD (n = 18) 1 1 10 5 1
MERS (n = 7) 3 2 2
Reye - like syndrome (n = 2) 2
AE (unclassified) (n = 6) 4 2
HHS (n = 1) 1
ANE (n = 1) 1
HIE (n = 1) 1
Intracranial bleeding (n = 1) 1
FS (n = 20) 1 6 11 2
ES (n = 11) 3 2 5 1
AE, acute encephalopathy; AESD, acute encephalopathy with biphasic seizures and late reduced diffusion; ANE, acute 
necrotizing encephalopathy; EEG, electroencephalogram; ES, epileptic status, FS, febrile seizure, MERS, mild encephalitis/
encephalopathy with a reversible splenial lesion, HIE, hypoxic-ischemic encephalopathy; HHS, hemiconvulsion-hemiplegia 
syndrome.
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showed a significantly high power value in the frontal 
and centro-parietal areas (Fig. 2B). In the alpha band, 
the AESD group showed a significantly lower power 
value than the FS group in the fronto-central areas (Fig. 
2C). In the beta band, the power value in the FS group 
was significantly higher than the AESD group in the F3-
C3 area (Table 4). The MERS group showed a higher 
beta band power with frontal predominance (Fig. 2D). 
In the gamma band, the FS group showed a significantly 
higher power value than the other groups in the centro-
parietal areas. Gamma band power in MERS was higher 
in the frontal areas compared to other groups (Table 4). 
The ratios of delta/alpha and (delta + theta)/(alpha + beta) 
in the AESD group were both higher than those in the 
other groups in the frontal and parietal predominance 
(Figs. 2E and F). In terms of the correlation between the 
band power and the prognosis, delta power was lower in 
the patients with the most severe outcome and higher in 
the patient group with mild—moderate sequelae in the 
frontal and right parieto-occipital areas (Table 5). 
Comparison of EEGs in AESD and FS by spectrum 
analyses including temporal evolution
Despite the significant differences revealed in the spec-
trum analysis among the different etiologies in the pa-
tient groups, there was still overlap in the spectra from 
each group. To identify further information for manage-
ment of individual patient for whom the distinction of 
AESD and FS was desired, we compared EEGs within 
24 h from onset in AESD (n = 7) and FS (n = 15) pa-
tients. The delta power values of these groups were not 
significantly different in any areas. The AESD group 
showed lower band powers than the FS group in the F3-
C3, F4-C4 and P3-O1 areas in the theta band, and in all 
areas in the alpha, beta, and gamma bands. The ratios of 
delta/alpha and (delta + theta)/(alpha + beta) were higher 
in the AESD group in all areas (Table 6).
 We then plotted the temporal distribution of spec-
trum band powers from the 22 patients and found that 
absolute theta and alpha band power tended to increase, 
and delta/alpha and (delta + theta)/(alpha + beta) ratios 
significantly decreased with time in the FS group (Fig. 
3). In the 4 patients [2 AESD (Patients 7 and 8; see Table 
1) and 2 FS (Patients 45 and 56)] for whom EEGs were 
repeatedly recorded within 24 h from onset, theta, al-
pha, and beta band powers were higher and/or increased 
with time, and the delta/alpha and (delta + theta)/(alpha 
+ beta) ratios remained lower from the early stage in the 
FS patients (Fig. 4).
DISCUSSION
This is the first report that quantitatively analyzed acute 
phase EEGs in childhood infection-related AEs with 
band spectrum powers. Significance of usual visual in-
spection of EEG was limited to the expectation of the 
most severe or mild outcomes, common to the cases 
of the AEs in a broad sense: slow and/or low voltage 
background, lack of EEG reactivity to external stimuli, 
and epileptiform discharges are characteristic in acute 
cerebral injuries with outcomes of various severities due 
to hypoxia-ischemia, bacterial infections, hepatic coma, 
and head trauma.1, 2, 9 Among others, isoelectric and/or 
discontinuous EEG patterns, which correspond to Grade 
5 in this study, have been linked to the poorest outcome 
in these etiologies.
 In previous reports, findings in EEG spectrum anal-
ysis from patients with AEs include a decreased (delta + 
theta)/(alpha + beta) ratio in severe bacterial infections,15 
and increased delta power and lower 50% spectral edge 
frequency in hepatic coma,14 all of which did not show 
significant correlation with prognosis. Although diffuse 
asymmetrical slow waves in various AE etiologies,16 and 
electrical storm in hemorrhagic shock and encephalopa-
thy syndrome17 are described as useful in outcome pre-
diction, these appear to be applicable to rather specific 
conditions.
 The band power analysis in this study among groups 
of different severity in outcomes revealed significant dif-
ference only in the delta frequency power bands in the 
frontal areas, which was lower in the most severe prog-
nosis group and higher in the mild-moderate prognosis 
group. This may represent the low-voltage or isoelectric 
Table 3. Relationship between the EEG severity grades during the acute phase and prognosis
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Normal (n = 54) 7 11 31 5
Mild-moderate (n = 4) 1 2 1
Severe (n = 5) 2 3
Most severe (n = 5) 1 1 3
EEG, electroencephalogram.
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Fig. 2. Spectrum analysis of EEGs in different etiologies. Absolute power of A: delta (0.5–3 Hz), B: theta (4–7 Hz), C: alpha (8–12 Hz) 
and D: beta (13–19 Hz) frequency bands, as well as the ratio of band powers, E: delta/alpha and F: (delta + theta)/(alpha + beta), are 
shown. Five vertical bars for each area, e.g. Fp2-F4, represent the groups of AESD, MERS, FS, ES and control from the left to the right. 
Vertical squares on each bar show 25, median and 75 percentile values. Dots on the right of the bars represent the values of individual 
subject. The dots enclosed by blank signs represent the patients whose EEG tracings are shown in Fig. 1 (○: grade 1, □: grade 2, △ : 
grade 3, ▽ : grade 4, ☓: grade 5). *P < 0.05, **P < 0.01. AESD, acute encephalopathy with biphasic seizures and late reduced diffusion; 
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Table 4. Power spectrum values of EEGs in children after status epilepticus due to each etiology Table 4-Continued
Frequency Patient group
Locations Locations
Fp1-F3 Fp2-F4 F3-C3 F4-C4 C3-P3 C4-P4 P3-O1 P4-O2
delta (µV2)
AESD  76380 (892–513043)  59377 (1407–319824)  75346 (161–457518)  66801 (168–309148)  65870 (71–420264)  92043 (412–472320)  109876 (122–580641)  113063 (784–601826)
MERS  80817 (3029–303123)  99577 (4824–378404)  62617 (3098–275621)  52807 (1808–283534)  68914 (3054–344211)  94172 (4492–345928)  53371 (4603–136840)  64119 (5122–167628)
FS  48315 (3210–171041)  37976 (4550–128664)  60494 (1472–326000)  55717 (1218–310697)  58728 (2133–291000)  41958 (1444–145000)  111192 (4223–423000)  78466 (2312–376309)
ES  23169 (7313–56033)  22168 (2994–82100)  28054 (1393–82363)  18963 (1567–53800)  27627 (840–150000)  32622 (1984–177000)  27550 (2083–153000)  34188 (148–158000)
Control  22200 (3186–69500)  23096 (3638–84100)  20603 (1740–68200)  23757 (2570–77000)  21398 (1315–75902)  23337 (949–120517)  48173 (1676–119967)  59700 (2124–202674)
theta (µV2)
AESD  1956 (33–14977) **  2154 (55–17872)**  1750 (8–7779)*  1662 (4–9400)  1533 (6–5752)*  1493 (11–5150)*  1835 (10–7307)*  1570 (22–5944)
MERS  8973 (300–28335) **, *  9970 (312–29121)**  7754 (364–22529)*  4520 (198–15201)  5417 (251–22572)*  9032 (522–38951)*  7115 (230–24193)*  5962 (282–14508)
FS  2978 (236–19977) *  2381 (350–7910)**  4253 (139–18426)  3714 (305–16900)  3189 (387–12800)  2965 (402–18900)*  3957 (429–21800)  3641 (322–27400)
EP  1939 (426–5804) *  1983 (174–4904)**  1687 (258–4554)*  2093 (235–3993)  1180 (243–2289)*  1448 (289–2937)*  1567 (234–4067)*  1351 (331–3408)
Control  1574 (618–3140) **  1984 (630–6770)**  1845 (975–3660)*  2044 (912–4750)  1635 (679–3950)  1558 (374–4438)*  2028 (894–5274)  2059 (825–5866)
alpha (µV2)
AESD  221 (14–965)**  242 (12–1203)  308 (4–1380)  269 (2–1257)*  220 (3–1293)  188 (6–920)*  218 (7–1552)  193 (9–457)
MERS  1117 (232–3014)**  1233 (170–4453)  776 (87–2291)  612 (206–1354)  770 (167–3132)  1028 (112–4635)*  605 (120–1185)  616 (143–1962)
FS  506 (41–1902)  502 (74–1640)  672 (47–2016)  623 (130–1370)*  429 (126–1099)  466 (70–1312)  433 (107–1652)  444 (78–2198)
ES  433 (98–1431)  453 (104–854)  453 (115–963)  519 (138–917)  277 (44–524)  389 (175–1293)  339 (55–1055)  304 (129–772)
Control  667 (75–3269)  651 (62–2737)  507 (107–1520)  444 (84–1020)  437 (119–1740)  372 (77–1610)  328 (141–903)  290 (116–510)
beta (µV2)
AESD  70 (6–298)**  62 (4–347)**  77 (2–452)*  72 (1–247)  88 (2–500)  70 (3–254)  90 (3–564)*  83 (6–529)
MERS  677 (32–2927)**, *  286 (35–958)**, *  177 (23–567)  82 (26–114)  108 (33–305)  188 (20–645)  454 (37–2285)*  116 (40–502)
FS  135 (23–586)**  134 (34–396)  247 (23–1260)*  290 (46–2072)  121 (37–8326)  166 (26–725)  132 (44–384)  154 (20–465)
ES  154 (16–516)*  107 (45–162)*  202 (20–567)  243 (53–1076)  84 (7–176)  157 (27–678)  96 (11–328)  145 (24–493)
Control  72 (22–212)**  81 (17–302)**  134 (25–447)  131 (19–531)  72 (26–228)  65 (27–164)  71 (25–150)*  68 (36–137)
gamma (µV2)
AESD  29 (1–211)**  19 (1–99)**  18 (1–136)*  21 (1–111)**  19 (1–94)**  20 (1–92)**  25 (1–110)  38 (1–335)
MERS  500 (2–2346)**, *  233 (1–887)**, *  32 (1–84)  17 (1–36)*  16 (1–30)  30 (1–89)  252 (1–1611)  20 (1–72)
FS  68 (13–311)**  66 (9–193)*  76 (8–309)*  84 (21–277)**, *  59 (8–268)**, *  69 (10–265)**, *  76 (6–352)  87 (10–362)
ES  67 (5–281)*  51 (9–164)*  79 (5–285)  51 (18–162)  28 (2–60)  63 (6–277)  37 (3–135)  82 (5–399)
Control  31 (10–81)**  32 (6–78)**  24 (6–67)  24 (6–55)**  22 (5–60)*  20 (5–64)*  26 (5–73)  24 (6–69)
Mean and the range of power values are shown in each cell. *P < 0.05, ** P < 0.01.
AESD, acute encephalopathy with biphasic seizures and late reduced diffusion; ES, epileptic status epilepticus; FS, febrile status epilepticus; 
MERS, mild encephalitis/encephalopathy with a reversible splenial lesion.
Table 5. Comparison of power spectrum values of EEGs between different severity groups of children after
status epilepticus Table 5-Continued
Frequency Prognosis
Locations Locations
Fp1-F3 (µV) Fp2-F4 (µV) F3-C3 (µV) F4-C4 (µV) C3-P3 (µV) C4-P4 (µV) P3-O1 (µV) P4-O2 (µV)
delta (µV2)
Most severe  27134 (130–127928)*  20164 (135–91042)  11516 (62–56556)*  12285 (43–49985)  23365 (11–114752)  25319 (32–116038)*  23312 (20–115912)  33022 (85–163056)
Severe  40583 (2445–120609)*  48629 (1194–179730)  59618 (4309–251536)  59131 (6489–233011)  69001 (2825–242085)  115692 (1739–472320)  153993 (2278–580641)  147245 (3383–559450)
Moderate–mild  157172 (2273–513034)**, *  113672 (4365–319824)*  137676 (2807–457517)*  102912 (4467–309148)  105818 (5165–420263)  165972(6766–464742)*  165137 (3859–569219)  185116 (9388–601826)
Normal  42520 (970–303122)**  40677 (1406–378404)*  46431 (1392–326000)*  41084 (1217–310697)  47111 (839–344211) 46940 (949–345928)*  74752 (1676–479000)  65355 (1481–376308)
theta (µV2)
Most severe  770 (15–3532)  592 (22–2471)  584 (7–2860)  387 (4–1530)  928 (2–4469)  812 (9–3725)  1342 (4–6630)  757 (9–3651)
Severe  1416 (133–5236)  1517 (86–5554)  1939 (267–7779)  1175 (92–3429)  1877 (265–5752)  1510 (143–5150)  2487 (180–7307)  1295 (131–3417)
Moderate–mild  1437 (401–4339)  1437 (670–3830)  1334 (499–3129)  1305 (863–1667)  952 (184–2578)  1522 (369–4483)  1720 (205–6123)  2042 (338–5943)
Normal  2860 (58–28335)  3064 (55–29121)  3043 (42–22529)  2709 (45–16900)  2444 (242–22572)  2913 (182–38951)  2962 (70–24193)  2721 (129–27400)
alpha (µV2)
Most severe  172 (6–751)  150 (11–596)  101 (4–481)  102 (2–376)  208 (1–876)  199 (6–865)  205 (1–984)  197 (3–899)
Severe  252 (34–964)  313 (17–1202)  347 (58–1380)  237 (9–727)  358 (27–1293)  289 (12–920)  452 (20–1551)  216 (20–445)
Moderate–mild  218 (16–426)  253 (24–742)  343 (34–1073)  380 (50–1256)  163 (8–407)  150 (34–280)  119 (19–241)  200 (33–330)
Normal  509 (8–3270)  529 (7–4453)  508 (6–2292)  490 (7–1370)  394 (29–3132)  443 (21–4635)  364 (11–1652)  349 (17–2198)
beta (µV2)
Most severe  45 (6–69)  41 (4–88)  46 (14–86)  69 (4–139)  68 (15–234)  75 (9–167)  30 (5–90)  31 (5–80)
Severe  65 (3–298)  61 (3–256)  35 (2–178)  36 (1–154)  65 (0–241)  66 (3–307)  55 (1–280)  64 (1–257)
Moderate–mild  36 (9–70)  31 (8–87)  40 (8–92)  48 (10–124)  27 (3–63)  42 (11–126)  32 (5–60)  40 (6–101)
Normal  192 (4–2928)  143 (3–958)  244 (3–4279)  188 (2–2071)  229 (7–8775)  135 (3–725)  148 (7–2285)  124 (8–529)
gamma (µV2)
Most severe  22 (2–88)  23 (2–85)  14 (1–65)  19 (0–73)  22 (0–66)  22 (1–80)  19 (1–78)  27 (1–85)
Severe  13 (0–37)  12 (0–40)  12 (0–53)  7 (0–25)  12 (1–46)  11 (0–35)  23 (1–62)  12 (1–28)
Moderate–mild  6 (1–14)  6 (1–18)  6 (1–19)  13 (1–54)  9 (1–41)  21 (2–92)  15 (1–56)  19 (0–68)
Normal  113 (2–2347)  80 (1–888)  71 (1–1300)  50 (1–277)  76 (1–2762)  47 (1–277)  70 (1–1611)  58 (0–362)
Mean and the range of power values are shown in each cell. *P < 0.05, ** P < 0.01. EEG, electroencephalogram.
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Table 4. Power spectrum values of EEGs in children after status epilepticus due to each etiology Table 4-Continued
Frequency Patient group
Locations Locations
Fp1-F3 Fp2-F4 F3-C3 F4-C4 C3-P3 C4-P4 P3-O1 P4-O2
delta (µV2)
AESD  76380 (892–513043)  59377 (1407–319824)  75346 (161–457518)  66801 (168–309148)  65870 (71–420264)  92043 (412–472320)  109876 (122–580641)  113063 (784–601826)
MERS  80817 (3029–303123)  99577 (4824–378404)  62617 (3098–275621)  52807 (1808–283534)  68914 (3054–344211)  94172 (4492–345928)  53371 (4603–136840)  64119 (5122–167628)
FS  48315 (3210–171041)  37976 (4550–128664)  60494 (1472–326000)  55717 (1218–310697)  58728 (2133–291000)  41958 (1444–145000)  111192 (4223–423000)  78466 (2312–376309)
ES  23169 (7313–56033)  22168 (2994–82100)  28054 (1393–82363)  18963 (1567–53800)  27627 (840–150000)  32622 (1984–177000)  27550 (2083–153000)  34188 (148–158000)
Control  22200 (3186–69500)  23096 (3638–84100)  20603 (1740–68200)  23757 (2570–77000)  21398 (1315–75902)  23337 (949–120517)  48173 (1676–119967)  59700 (2124–202674)
theta (µV2)
AESD  1956 (33–14977) **  2154 (55–17872)**  1750 (8–7779)*  1662 (4–9400)  1533 (6–5752)*  1493 (11–5150)*  1835 (10–7307)*  1570 (22–5944)
MERS  8973 (300–28335) **, *  9970 (312–29121)**  7754 (364–22529)*  4520 (198–15201)  5417 (251–22572)*  9032 (522–38951)*  7115 (230–24193)*  5962 (282–14508)
FS  2978 (236–19977) *  2381 (350–7910)**  4253 (139–18426)  3714 (305–16900)  3189 (387–12800)  2965 (402–18900)*  3957 (429–21800)  3641 (322–27400)
EP  1939 (426–5804) *  1983 (174–4904)**  1687 (258–4554)*  2093 (235–3993)  1180 (243–2289)*  1448 (289–2937)*  1567 (234–4067)*  1351 (331–3408)
Control  1574 (618–3140) **  1984 (630–6770)**  1845 (975–3660)*  2044 (912–4750)  1635 (679–3950)  1558 (374–4438)*  2028 (894–5274)  2059 (825–5866)
alpha (µV2)
AESD  221 (14–965)**  242 (12–1203)  308 (4–1380)  269 (2–1257)*  220 (3–1293)  188 (6–920)*  218 (7–1552)  193 (9–457)
MERS  1117 (232–3014)**  1233 (170–4453)  776 (87–2291)  612 (206–1354)  770 (167–3132)  1028 (112–4635)*  605 (120–1185)  616 (143–1962)
FS  506 (41–1902)  502 (74–1640)  672 (47–2016)  623 (130–1370)*  429 (126–1099)  466 (70–1312)  433 (107–1652)  444 (78–2198)
ES  433 (98–1431)  453 (104–854)  453 (115–963)  519 (138–917)  277 (44–524)  389 (175–1293)  339 (55–1055)  304 (129–772)
Control  667 (75–3269)  651 (62–2737)  507 (107–1520)  444 (84–1020)  437 (119–1740)  372 (77–1610)  328 (141–903)  290 (116–510)
beta (µV2)
AESD  70 (6–298)**  62 (4–347)**  77 (2–452)*  72 (1–247)  88 (2–500)  70 (3–254)  90 (3–564)*  83 (6–529)
MERS  677 (32–2927)**, *  286 (35–958)**, *  177 (23–567)  82 (26–114)  108 (33–305)  188 (20–645)  454 (37–2285)*  116 (40–502)
FS  135 (23–586)**  134 (34–396)  247 (23–1260)*  290 (46–2072)  121 (37–8326)  166 (26–725)  132 (44–384)  154 (20–465)
ES  154 (16–516)*  107 (45–162)*  202 (20–567)  243 (53–1076)  84 (7–176)  157 (27–678)  96 (11–328)  145 (24–493)
Control  72 (22–212)**  81 (17–302)**  134 (25–447)  131 (19–531)  72 (26–228)  65 (27–164)  71 (25–150)*  68 (36–137)
gamma (µV2)
AESD  29 (1–211)**  19 (1–99)**  18 (1–136)*  21 (1–111)**  19 (1–94)**  20 (1–92)**  25 (1–110)  38 (1–335)
MERS  500 (2–2346)**, *  233 (1–887)**, *  32 (1–84)  17 (1–36)*  16 (1–30)  30 (1–89)  252 (1–1611)  20 (1–72)
FS  68 (13–311)**  66 (9–193)*  76 (8–309)*  84 (21–277)**, *  59 (8–268)**, *  69 (10–265)**, *  76 (6–352)  87 (10–362)
ES  67 (5–281)*  51 (9–164)*  79 (5–285)  51 (18–162)  28 (2–60)  63 (6–277)  37 (3–135)  82 (5–399)
Control  31 (10–81)**  32 (6–78)**  24 (6–67)  24 (6–55)**  22 (5–60)*  20 (5–64)*  26 (5–73)  24 (6–69)
Mean and the range of power values are shown in each cell. *P < 0.05, ** P < 0.01.
AESD, acute encephalopathy with biphasic seizures and late reduced diffusion; ES, epileptic status epilepticus; FS, febrile status epilepticus; 
MERS, mild encephalitis/encephalopathy with a reversible splenial lesion.
Table 5. Comparison of power spectrum values of EEGs between different severity groups of children after
status epilepticus Table 5-Continued
Frequency Prognosis
Locations Locations
Fp1-F3 (µV) Fp2-F4 (µV) F3-C3 (µV) F4-C4 (µV) C3-P3 (µV) C4-P4 (µV) P3-O1 (µV) P4-O2 (µV)
delta (µV2)
Most severe  27134 (130–127928)*  20164 (135–91042)  11516 (62–56556)*  12285 (43–49985)  23365 (11–114752)  25319 (32–116038)*  23312 (20–115912)  33022 (85–163056)
Severe  40583 (2445–120609)*  48629 (1194–179730)  59618 (4309–251536)  59131 (6489–233011)  69001 (2825–242085)  115692 (1739–472320)  153993 (2278–580641)  147245 (3383–559450)
Moderate–mild  157172 (2273–513034)**, *  113672 (4365–319824)*  137676 (2807–457517)*  102912 (4467–309148)  105818 (5165–420263)  165972(6766–464742)*  165137 (3859–569219)  185116 (9388–601826)
Normal  42520 (970–303122)**  40677 (1406–378404)*  46431 (1392–326000)*  41084 (1217–310697)  47111 (839–344211) 46940 (949–345928)*  74752 (1676–479000)  65355 (1481–376308)
theta (µV2)
Most severe  770 (15–3532)  592 (22–2471)  584 (7–2860)  387 (4–1530)  928 (2–4469)  812 (9–3725)  1342 (4–6630)  757 (9–3651)
Severe  1416 (133–5236)  1517 (86–5554)  1939 (267–7779)  1175 (92–3429)  1877 (265–5752)  1510 (143–5150)  2487 (180–7307)  1295 (131–3417)
Moderate–mild  1437 (401–4339)  1437 (670–3830)  1334 (499–3129)  1305 (863–1667)  952 (184–2578)  1522 (369–4483)  1720 (205–6123)  2042 (338–5943)
Normal  2860 (58–28335)  3064 (55–29121)  3043 (42–22529)  2709 (45–16900)  2444 (242–22572)  2913 (182–38951)  2962 (70–24193)  2721 (129–27400)
alpha (µV2)
Most severe  172 (6–751)  150 (11–596)  101 (4–481)  102 (2–376)  208 (1–876)  199 (6–865)  205 (1–984)  197 (3–899)
Severe  252 (34–964)  313 (17–1202)  347 (58–1380)  237 (9–727)  358 (27–1293)  289 (12–920)  452 (20–1551)  216 (20–445)
Moderate–mild  218 (16–426)  253 (24–742)  343 (34–1073)  380 (50–1256)  163 (8–407)  150 (34–280)  119 (19–241)  200 (33–330)
Normal  509 (8–3270)  529 (7–4453)  508 (6–2292)  490 (7–1370)  394 (29–3132)  443 (21–4635)  364 (11–1652)  349 (17–2198)
beta (µV2)
Most severe  45 (6–69)  41 (4–88)  46 (14–86)  69 (4–139)  68 (15–234)  75 (9–167)  30 (5–90)  31 (5–80)
Severe  65 (3–298)  61 (3–256)  35 (2–178)  36 (1–154)  65 (0–241)  66 (3–307)  55 (1–280)  64 (1–257)
Moderate–mild  36 (9–70)  31 (8–87)  40 (8–92)  48 (10–124)  27 (3–63)  42 (11–126)  32 (5–60)  40 (6–101)
Normal  192 (4–2928)  143 (3–958)  244 (3–4279)  188 (2–2071)  229 (7–8775)  135 (3–725)  148 (7–2285)  124 (8–529)
gamma (µV2)
Most severe  22 (2–88)  23 (2–85)  14 (1–65)  19 (0–73)  22 (0–66)  22 (1–80)  19 (1–78)  27 (1–85)
Severe  13 (0–37)  12 (0–40)  12 (0–53)  7 (0–25)  12 (1–46)  11 (0–35)  23 (1–62)  12 (1–28)
Moderate–mild  6 (1–14)  6 (1–18)  6 (1–19)  13 (1–54)  9 (1–41)  21 (2–92)  15 (1–56)  19 (0–68)
Normal  113 (2–2347)  80 (1–888)  71 (1–1300)  50 (1–277)  76 (1–2762)  47 (1–277)  70 (1–1611)  58 (0–362)
Mean and the range of power values are shown in each cell. *P < 0.05, ** P < 0.01. EEG, electroencephalogram.
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Fig. 3. Temporal distribution of spectrum band powers in AESD and FS within 24 h after the onset of seizures. Corresponding regres-
sion lines (the solid line for the AESD group and the dotted line for the FS group) are drawn for each of the 2 groups. The power value 
at C4–P4 area was chosen for demonstration. Blank and filled circles represent the FS (n = 15) and AESD (n = 7) patients. A: delta, B: 
theta, C: alpha, and D: beta frequency bands, and E: delta/alpha and F: (delta + theta)/(alpha + beta) ratios. Note that alpha power in FS 
significantly increases (C), and the ratios of delta/alpha and (delta + theta)/(alpha + beta) in FS decrease (E and F) with time. AESD, acute 
encephalopathy with biphasic seizures and late reduced diffusion; FS, febrile seizure.
AESD;	  r =	  –0.13	  	  	  	  	  	  	  	  	  	  	  	  
P	  =	  	  	  0.78	  
	  FS;	  r	  =	  –0.33	  
	  	  	  	  	  	  	  	  	  	  	  P	  =	  	  	  0.21
AESD;	  r	  =	  –0.34	  	  	  	  	  	  	  	  	  	  	  	  
P	  =	  	  	  0.45	  
	  FS;	  r	  =	  	  	  0.42	  
	  	  	  	  	  	  	  	  	  	  	  P	  =	  	  	  0.11
	  	  	  	  	  	  	  	  	  	  	  P	  =	  	  	  0.12
	  	  	  	  	  	  	  	  	  	  	  P	  =	  	  	  0.90
0 1 0 2 0 3 0
0
1 0 0 0 0 0
2 0 0 0 0 0
3 0 0 0 0 0
4 0 0 0 0 0
5 0 0 0 0 0









(h o u rs )(h)	




0 1 0 2 0 3 0
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0
2 0 0 0 0




(h o u rs )(h)	




0 1 0 2 0 3 0
0
5 0 0
1 0 0 0
1 5 0 0




(h o u rs )(h)	














(h o u rs )(h)	




1 0 0 0
1 5 0 0
2 0 0 0
2 5 0 0
3 0 0 0
R e c o rd in g  t im e  fro m  o n s e t
(% )
(h o u rs ))	
Recording	  Ame	  fr 	   s t
0 1 0 2 0 3 0
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
2 5 0 0
R e c o rd in g  t im e  fro m  o n s e t
(% )
(h o u rs )(h)	
Recording	  Ame	  from	  onset	




AESD;	  r =	  –0.59	  	  	   
P	  =	  	  	  0.17  	  
AESD;	  r =	  –0.53	  
 P	  =	  	  	  0.22	  
	  FS;	  r	  =	  	  	  0.03	  







AESD;	  r =  	  0.73	  	  	   
P	  =	  	  	  0.06  	  
FS;	  r =	  –0.56	  	  	   
P	  =	  	  	  0.02  	  
AESD;	  r =  	  0.69  
 P	  =	  	  	  0.09
FS;	  r =	  –0.56	  	  	   
P	  =	  	  	  0.02  	  








EEG analysis in acute encephalopathy
Fig. 4. Evolution of band powers in individuals for whom EEGs were recorded twice within 24 h after the onset of seizures. The power 
values at C4–P4 area are shown. Solid and dotted lines represent the AESD and the FS patients, respectively. and A: delta, B: theta, C: 
alpha and D: beta frequency bands, and E: delta/alpha and F: (delta + theta)/(alpha + beta) ratios. AESD, acute encephalopathy with bi-

























recording	  ,me	  from	  onset	 recording	  ,me	  from	  onset	
Recording	  ,me	  from	  onset	 Recording	  ,me	  from	  onset	


































recording	  ,me	  from	  onset	 recording	  ,me	  from	  onset	
Recording	  ,me	  from	  onset	 Recording	  ,me	  from	  onset	


































recording	  ,me	  from	  onset	 recording	  ,me	  from	  onset	
Recording	  ,me	  from	  onset	 Recording	  ,me	  from	  onset	

















M. Oguri et al.
Table 6. Comparison of AESD and FS power spectrum value in EEGs within 24 h from onset Table 6-Continued
Frequency Patient group
Locations Locations
Fp1-F3 Fp2-F4 F3-C3 F4-C4 C3-P3 C4-P4 P3-O1 P4-O2
delta (µV2)
AESD  139812 (6575–513043)  97891 (6557–319824)  131689 (703–457517)  110619 (7152–309148)  99733 (1922–420263)  127946 (9967–464742)  130996 (122–569219)  152357 (1079–601826)
FS  55493 (3210–171041)  42645 (4550–128664)  69815 (5188–32600)  62161 (4249–310697)  60333 (4160–291000)  43634 (3240–145000)  123128 (4223–423000)  80667 (5526–376308)
theta (µV2)
AESD  3340 (133–14977)  3633 (86–17872)  1935 (27–7345)  2181 (92–9399)  1247 (156–2981)  1824 (143–4483)  1668 (28–6123)  1859 (83–5943)
FS  3639 (236–19977)  2894 (417–7910)  4764 (495–18426)  4198 (644–16900)  3392 (421–12800)  3265 (402–18900)  4385 (759–21800)  3924 (614–27400)
alpha (µV2)
AESD  170 (5–341)  171 (17–524)  200 (10–634)  213 (9–676)  120 (27–190)  151 (13–280)  90 (19–241)  46 (20–331)
FS  559 (41–1902)  563 (74–1640)  738 (107–2016)  688 (139–1370)  428 (126–1099)  491 (80–1312)  455 (190–1652)  467 (101–2198)
beta (µV2)
AESD  36 (7–84)  30 (6–70)  37 (6–92)  43 (2–101)  39 (12–126)  43 (3–120)  24 (7–52)  43 (6–101)
FS  147 (23–586)  150 (34–396)  275 (46–1259)  328 (58–2071)  123 (37–326)  179 (26–724)  140 (60–384)  166 (20–464)
gamma (µV2)
AESD  9 (1–35)  8 (1–28)  6 (1–20)  9 (1–21)  9 (1–40)  9 (1–31)  6 (1–12)  11 (1–36)
FS  73 (13–310)  73 (9–192)  79 (13–309)  91 (20–276)  59 (8–268)  71 (11–264)  82 (6–351)  91 (10–362)
delta/alpha(%)
AESD  685 (81–1710)  629 (78–1520)  881 (64–2990)  900 (117–2836)  898 (12–2531)  981 (100–2587)  1120 (6–2361)  1212 (15–2610)
FS  144 (12–778)  121 (13–629)  107 (3–359)  102 (3–450)  168 (4–829)  138 (3–462)  350 (2–901)  262 (3–990)
(delta + theta)/(alpha + beta)
(%)
AESD  577 (59–1586)  515 (55–1192)  743 (46–2744)  727 (91–2586)  734 (7–2376)  815 (69–2080)  903 (4–2110)  991 (7–1888)
FS  112 (15–609)  96 (12–492)  82 (6–276)  77 (5–337)  138 (6–727)  107 (5–336)  250 (5–637)  183 (5–589)
Mean and the range of power values are shown in each cell. *P < 0.05, **P < 0.01.
AESD, acute encephalopathy with biphasic seizures and late reduced diffusion; EEG, electroencephalogram; ES, epileptic status epilepticus; 
FS, febrile status epilepticus; MERS, mild encephalitis/encephalopathy with a reversible splenial lesion.
EEGs in the most severe group. As for the differences 
among the background conditions, higher theta band 
power was characteristic in the MERS group. AESD 
group showed higher delta/alpha and (delta + theta)/
(alpha + beta) ratios in the frontal and parieto-occpital 
areas than the FS group. In contrast, delta band power 
was comparable between FS and AESD groups. These 
could be interpreted that EEGs in AESD are more mo-
notonous with decreased power of alpha and beta bands 
compared to those in FS. Thus, significant difference 
was found between AESD and FS but there was some 
overlap when focusing on individual patients (Fig. 2) 
based on the EEG within 120 h from the onset of first 
seizures.
 Interestingly, Synek et al.9 found that EEGs at 24–
48 h from onset of anoxic and traumatic cerebral injury 
was reliable than those during earlier phases in predic-
tion of outcome. Temporal evolution of EEG may also be 
indicative of the etiology and severity of the childhood 
infection-related AEs. This prompted us to compare the 
EEGs in AESD and FS within the first 24 h in terms of 
time-dependent changes. Although the number of EEGs 
in AESD between 5 and 24 h were limited, increase of 
alpha and beta power bands with time was apparent on 
EEGs in FS compared to those in AESD (Figs. 3 and 4). 
These suggest that serial EEGs up to 24 h after the onset 
would enhance the quality in early diagnosis of AESD 
before the emergence of second phase. Initial EEG earli-
est after admission would be also helpful for identifica-
tion of most severe cases of AESD.
 A nationwide survey identified 282 AESD cases 
per 3 years in Japan,3 which is presumably higher than 
other countries. The prevalence of FSs in Japan18 is 
higher than Caucasian countries,19 which may suggest 
a link between FS and AESD.5 On the other hand, FS 
is more prevalent in boys than girls,18, 20, 21 whereas the 
male-predominance was not observed in AESD (M:F 
= 114:167).3 This is suggestive of certain genetic predis-
position factors for AESD other than those for FSs in 
general. These may include certain genotype of carni-
tine palmitoyl transferase II,22, 23 SCN1A,24 SCN2A,25 
ADORA2A,26 and TLR3.27 These vulnerability factors to 
AESD may result in the persistent increase of excitatory 
transmitters assumed in the pathogenesis of AESD.8 
Subclinical status epilepticus has been identified in an 
AESD patient at the onset of the second phase.28 This 
phenomenon was not found in the present patient series; 
however, considering the pathogenesis of AESD, early 
diagnosis could lead to improve the prognosis through 
early decision of treatment with some agents reported as 
potentially effective for AESD. These include fosphe-
nytoin,28, 29 L-carnitine and vitamins,30 and erythropoi-
etin.31 The present study supports that follow-up EEGs 
up to 24 h from the onset would be helpful for early 
identification of AESD patients. EEG findings of AESD 
between 5 and 20 h from the onset, as well as any effect 
of the aforementioned treatment options, would be worth 
for further examination.
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